Freitag, 8 Nov. 2024
MIND Foundation Office, Boxhagener Str. 78, 10245 Berlin, Germany
Is psilocybin therapy on the horizon? Learn how MIND & OVID are shaping the future of mental health with cutting-edge psychedelic science
Psychedelic-assisted psychotherapy is entering mainstream discourse, and the MIND Foundation is a key actor in bringing this treatment into the public health insurance system. We recently completed the world’s largest publicly funded (BMBF) clinical trial with psilocybin for depression as junior partners of ZI Mannheim and Charité Berlin. MIND is now preparing a phase-III trial that will bring psilocybin therapy to patients in a legal, safe, evidence-based, and accessible way.
A value-based scientific approach is crucial for a sustainable re-introduction of psychedelic substances, especially now in times of growing public interest.
We need to be clear about both potentials and risks of psychedelics as we take it out of a niche and into the center of society.
The event is free and no registration required. First come first served.
16:00 – 17:00 Uhr | Doors open Immersive VR experience, networking |
17.00 – 17:45 Uhr | Current state of psychedelic therapies within the German health care system Dr. med. Andrea Jungaberle |
17.45 – 18:15 Uhr | Preparing, experiencing and integrating psilocybin therapy - stories from patients Christopher Schmidt, M.Sc. |
18:30 – 19:00 Uhr | Ketamine-Augmented Psychotherapy in Practice Dr. med. Marc Bos |
19:00 – 19.30 Uhr | From niche to mainstream: The role of MIND’s non-clinical psychedelic integration programs Victor Jivanescu, M.Sc. |
19:30 – 20:00 Uhr | What we need to bring psychedelic therapy into public health care Dr. Henrik Jungaberle |
20:00 | Networking |